Summary
Global Markets Direct’s, ‘Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Pipeline Review, H1 2016’, provides in depth analysis on Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted pipeline therapeutics.
The report provides comprehensive information on the Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166)
- The report reviews Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects
- The report assesses Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Momenta Pharmaceuticals, Inc.
Progen Pharmaceuticals Limited
Sigma-Tau S.p.A.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) Overview 7
Therapeutics Development 8
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Stage of Development 8
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Therapy Area 9
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Indication 10
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Companies 14
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Universities/Institutes 16
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Companies Involved in Therapeutics Development 24
Momenta Pharmaceuticals, Inc. 24
Progen Pharmaceuticals Limited 25
Sigma-Tau S.p.A. 26
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Drug Profiles 27
Antibodies to Inhibit Heparanase for Oncology - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Drug to Inhibit Heparanase for Lung Cancer and Pancreatic Cancer - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
necuparanib - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
PG-545 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
roneparstat - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Target Heparanase for Oncology, Immunology and Diabetes - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Dormant Projects 40
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Discontinued Products 41
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Featured News & Press Releases 42
Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 42
Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 42
Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 42
May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 43
Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer 44
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer 44
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer 45
Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives’ Patent 46
Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer 46
Oct 29, 2013: PG545 Phase 1 Cancer Trial Update 47
Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics 48
May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001 48
Jul 02, 2012: Momenta Pharma Doses First Patient With M402 In Phase I/II Clinical Trial In Metastatic Pancreatic Cancer 49
Jun 04, 2012: Momenta Pharma Presents Positive Preclinical Results Of M402 In Combination With Gemcitabine At ASCO 2012 Annual Meeting 50
May 30, 2012: Progen Pharma Obtains Australian Patent For Heparan Sulfate Mimetic Compounds 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53
List of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Assessment by Monotherapy/Combination Products, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 21
Number of Products by Stage and Molecule Type, H1 2016 23
Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 24
Pipeline by Progen Pharmaceuticals Limited, H1 2016 25
Pipeline by Sigma-Tau S.p.A., H1 2016 26
Dormant Projects, H1 2016 40
Discontinued Products, H1 2016 41
List of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 18
Number of Products by Stage and Mechanism of Actions, H1 2016 19
Number of Products by Routes of Administration, H1 2016 20
Number of Products by Stage and Routes of Administration, H1 2016 20
Number of Products by Molecule Types, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 22
